Navigation Links
Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008
Date:2/29/2008

BETHESDA, Md., Feb. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on Tuesday, March 4, 2008, at 10:30 am ET at the W Hotel in New York.

Dr. Itin's presentation will be available on Micromet's website at http://www.micromet-inc.com following the event.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform, is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical tri
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Micromet to Present at Two Upcoming Investor Conferences
2. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
3. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
4. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
5. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Program Connects Customers with ...Collected with DNA Genotek Products , ...-- DNA Genotek , a leading provider of products f... preparation, today announced its new global partn...ments for DNA Genotek,s partner community and is d...
(Date:11/23/2009)...IGN, Ill. You can think of it as origami very hi...of Illinois have developed a technique for fabrica... structures from thin films by coupling photolitho...ary interactions. , The films, only a few microns...ossible with thicker pieces of the same material. ...
(Date:11/23/2009)...MISSISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioS...oductdevelopmentcompanythatidentifiesandadvancesad...variousstagesofdevelopment,todayreportedthatCytopi...valuatingCYT387,apotent,orally-administeredJAK1/JA...Rochester,Minnesota.AproposaltomergeCytopiaintoYMh...
(Date:11/23/2009)...BURNABY,BC,Nov.23/PRNewswire/-InimexPharmaceutical...ams,Ph.DasitsPresidentandCEO. ,, Abramsbringsmo...cetoInimex.Heisaco-inventorofthenuclearmedicineima...sonMatthey,plcwherehewasManager,BiomedicalResearch...DinLangley,BCandwasPresidentandCEOfrom1996to2006.A...
Breaking Biology Technology:DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Inimex Announces Appointment of New CEO 2
...udies Presented at American Society for Metabolic ... Meeting, SAN CLEMENTE, Calif., June 23 USGI M...perts presented clinical evidence showing,that its...urgeons and,physicians to use an incisionless tech...stoma in patients who,ve regained weight after ini...
...W YORK, June 23 Bion Environmental,Technologies, ...,capabilities and performance of its comprehensive...ared to anaerobic digesters., Anaerobic or methan...rom livestock waste since the late 1800s. While it...ill based on a biological process that,produces bi...
...OTTSDALE, Ariz., June 23 MedPredict has published...ic insight for pharma and,biotech companies hoping...nagement. The report, entitled "Thought Leader Ins...depth interviews conducted with a panel of,special...gastroenterology,and primary care., The diagnosis...
Other Biology Technology:Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 3Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 4Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 5Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 6Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 7In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict 2
(Date:11/23/2009)...ersity of New Hampshire microbiologist Louis Tisa ...ce understanding of the actinorhizal plants, wides...nt-poor and contaminated soils. , The United St..., a professor of molecular, cellular and biomedica...tionship between the bacteria Frankia and Casuarin...
(Date:11/23/2009)...tring of recent discoveries about the multiple hea...this multi-purpose nutrient, increased awareness o...it, spurred research and even led to an appreciati...anging from the health of your immune system to pr...o influenza, vitamin D is now seen as one of the m...
(Date:11/23/2009)...te of General Medical Sciences (NIGMS), part of th...g $42.3 million for grants in scientific areas it ...loped the GO grant program to stimulate biomedical...the American Recovery and Reinvestment Act (Recove...mise to have a significant impact on a field of bi...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 1Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 2Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 3Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 1Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 2In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 1In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 2
...rtebrates with separate sexes, sex determination c...D). TSD is very common in reptiles, where the ambi...development irreversibly determines whether an ind...s and females in a population is the sex ratio, a ...iability. , A number of previous studies have als...
...silencing techniques and induced pluripotent stem ...hes to Parkinson,s drug development funded through...novation Awards 2008. As part of its mission to dr...he Foundation has awarded $1.1 million for 15 high...ojects under the initiative in the first half of t...
...pringer authors Monica Turner and Stuart Chapin wi...cal Society of America (ESA). Turner is the winner...d for outstanding ecological achievement. Chapin i...aper "Policy strategies to address sustainability ...onally changing climate". He shares the honor with...
Other Biology News:Fish with temperature-dependent sex determination face global warming 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinson's Disease 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinson's Disease 32 Springer authors win important awards from the Ecological Society of America 2
8 Channel Syringe Dispenser, 20 cc Capacity from Biosearch Technologies
HRP-STABILPLUS from AbD Serotec
...00RT rotary tables offer precision motorized rotat...mpatible with Parkers linear positioners and its l...axis configurations., , Preloaded, precision worm... preloaded angular contact support bearing , Runou...
Goat Anti-Wnt-1 (G-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: